Kurecetyl-A Tablet is a combination pharmaceutical formulation containing Acebrophylline 100 mg and Acetylcysteine 600 mg, designed for the management of respiratory disorders characterized by bronchial obstruction and excessive mucus production. Acebrophylline, a xanthine derivative with bronchodilator and mucosecretolytic properties, facilitates airway relaxation by inhibiting phosphodiesterase enzymes, thereby improving airflow and reducing bronchospasm. Concurrently, Acetylcysteine acts as a mucolytic agent by breaking disulfide bonds within mucus glycoproteins, leading to decreased viscosity and enhanced clearance of bronchial secretions. This dual-action mechanism makes Kurecetyl-A effective in treating conditions such as chronic obstructive pulmonary disease (COPD), bronchitis, and asthma exacerbations where mucus hypersecretion and airway constriction are prominent. The combination improves respiratory function, alleviates symptoms like cough and dyspnea, and aids in the prevention of recurrent infections by promoting expectoration. Kurecetyl-A is typically administered orally under medical supervision, with dosage adjusted according to clinical response and patient tolerance. Caution is advised in patients with hypersensitivity to xanthines or acetylcysteine, and monitoring is recommended for potential adverse effects such as gastrointestinal discomfort or allergic reactions. Overall, Kurecetyl-A Tablet offers a synergistic therapeutic approach for enhanced management of obstructive airway diseases.